Celladon, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, has appointed Michael Narachi chairman of the board of directors.
Michael currently is president and CEO of Orexigen Therapeutics. Michael has 29 years of biotechnology and pharmaceutical experience across a range of functions including clinical development, commercialization, strategic business development and planning. Previously, Michael was chairman, chief executive officer and president of Ren Pharmaceuticals, a private biotechnology company, and executive chairman of the board of Naryx Pharma, a private pharmaceutical company. In 2004, Narachi retired as an officer and vice president and general manager of Amgen's anemia business. He also is chairman of AMAG Pharmaceuticals and a member of the board at the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA).